ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
US Tech 100
18,374.40
0.31%
Dow Jones
39,069.59
0.00%
Brent Oil
83.065
0.27%
Bitcoin
68,199.38
-1.72%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Ikena Oncology Inc (IKNA) Quote

Ikena Oncology Inc

Ikena Oncology Inc (IKNA)

NASDAQ
1.33
0.05
(3.91%)
Closed May 24 4:00PM
Delayed by 15 minutes
1.33
0.00
( 0.00% )
Pre Market: 7:51AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.33
Bid
1.29
Ask
1.38
Volume
-
0.00 Day's Range 0.00
1.02 52 Week Range 7.38
Market Cap
64.183M
Previous Close
1.33
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
259,149
Shares Outstanding
48,258,111
Dividend Yield
-
PE Ratio
-0.94
Earnings Per Share (EPS)
-1.41
Revenue
9.16M
Net Profit
-68.17M

About Ikena Oncology Inc

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.ikenaoncology.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Ikena Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IKNA. The last closing price for Ikena Oncology was $1.33. Over the last year, Ikena Oncology shares have traded in a share price range of $ 1.02 to $ 7.38.

Ikena Oncology currently has 48,258,111 shares outstanding. The market capitalization of Ikena Oncology is $64.18 million. Ikena Oncology has a price to earnings ratio (PE ratio) of -0.94.

IKNA Latest News

More News

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and...

May 13 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13 2024
Edgar (US Regulatory)

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...

April 10 2024
GlobeNewswire Inc.

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients...

March 12 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...

February 27 2024
GlobeNewswire Inc.

Form 8-K - Current report

February 21 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.08-5.673758865251.411.4251.281071631.32439611CS
40.021.526717557251.311.471.281844961.34459871CS
12-0.13-8.904109589041.461.651.222591491.40230066CS
26-0.28-17.39130434781.612.321.222965631.47436099CS
52-4.68-77.87021630626.017.381.022231182.30133461CS
156-18.08-93.147861926819.4119.71.021615315.22366067CS
260-21.07-94.062522.437.611.021665306.60225854CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STSSSharps Technology Inc
$ 0.6207
(189.64%)
52.35M
INSMInsmed Inc
$ 51.70
(135.00%)
2.68M
POAIPredictive Oncology Inc
$ 2.69
(71.39%)
6.47M
CALTCalliditas Therapeutics AB
$ 38.28
(70.74%)
3.59k
NTRPNextTrip Inc
$ 2.99
(30.00%)
19
MRAIMarpai Inc
$ 1.16
(-40.21%)
40.18k
LUCYInnovative Eyewear Inc
$ 0.6814
(-30.68%)
5.57M
ONMDOneMedNet Corporation
$ 1.85
(-19.57%)
673.82k
LICNLichen China Limited
$ 1.20
(-17.24%)
10.06k
PEVPhoenix Motor Inc
$ 0.6394
(-17.00%)
57
STSSSharps Technology Inc
$ 0.616
(187.45%)
52.38M
CRKNCrown Electrokinetics Corporation
$ 0.1189
(17.72%)
41.04M
GWAVGreenwave Technology Solutions Inc
$ 0.0805
(-5.18%)
15.63M
TKLFYoshitsu Company Ltd
$ 0.3765
(25.50%)
11.19M
PEGYPineapple Energy Inc
$ 0.225
(26.33%)
9.82M

IKNA Discussion

View Posts
Monksdream Monksdream 2 months ago
IKNA under $2=
👍️0
Monksdream Monksdream 3 months ago
IKNA under $2
👍️0
herbied47 herbied47 7 months ago
$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
👍️0
herbied47 herbied47 7 months ago
Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
👍️0
Tacostocks Tacostocks 7 months ago
It went down, because it didnt have the backing of Money hunt...
👍️0
Money hunt Money hunt 7 months ago
what happened here my short friend
👍️0
Tacostocks Tacostocks 7 months ago
Aged like milk eh
👍️0
AJ Freely AJ Freely 10 months ago
$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics
👍️0
Tartiaboy Tartiaboy 1 year ago
This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
IKNA look at this beast
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
IKNA monster
👍️0
crudeoil24 crudeoil24 3 years ago
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
👍️0

Your Recent History

NASDAQ
IKNA
Ikena Oncology
BOV
DESK3M
Desktop - Sigmanet Comun... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved